Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

Based on the previously described roles of doxorubicin in immunogenic cell death, both doxorubicin and liposomal doxorubicin (Doxil) were evaluated for their ability to boost the antitumor response of different cancer immunotherapies including checkpoint blockers (anti–PD-L1, PD-1, and CTLA-4 mAbs)...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neoplasia
Main Authors: Rios-Doria, Jonathan, Durham, Nicholas, Wetzel, Leslie, Rothstein, Raymond, Chesebrough, Jon, Holoweckyj, Nicholas, Zhao, Wei, Leow, Ching Ching, Hollingsworth, Robert
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4674486/
https://ncbi.nlm.nih.gov/pubmed/26408258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2015.08.004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares